Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

NCT ID: NCT01069809

Last Updated: 2017-01-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 53 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-07-31
• Study Completion Date: 2015-09-30

Brief Summary

The purpose of this study is to determine the safety and effectiveness of AGS-004, an immune therapy, for HIV-infected individuals. Safety and effectiveness will be tested while the individuals are both taking antiretroviral therapy (ART) medication and interrupting ART medication.

Detailed Description

The purpose of this study is to determine the safety and effectiveness of AGS-004, an immune therapy, for HIV-infected individuals. Safety and effectiveness will be tested while the individuals are both taking antiretroviral therapy (ART) medication and interrupting ART medication

Conditions

HIV Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

AGS-004

HIV-1 Immune Therapy

Group Type: EXPERIMENTAL

AGS-004

Intervention Type: BIOLOGICAL

HIV-1 Immune Therapy

Inactive Injection

Inactive Placebo Injection

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: BIOLOGICAL

Inactive Placebo Injection

Interventions

AGS-004

HIV-1 Immune Therapy

Intervention Type: BIOLOGICAL

Placebo

Inactive Placebo Injection

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Males and females ≥ 18 to 60 years of age.

2. HIV infection.

3. Stable ART regimen for ≥ 3 months prior to Screening.

4. HIV VL level ≤ 400 copies/mL for ≥ 2 months prior to Screening.

5. HIV VL level ≤ 50 copies/mL at Screening.

6. CD4+ T cell count ≥ 450 cells/mm3 at Screening.

7. Pre-ART nadir CD4+ T cell counts ≥ 200 cells/mm³.

8. Availability of an adequate sample of frozen plasma most recently collected (no more than 90 days and preferably within 30 days) before starting ART.

9. Laboratory values within pre-defined limits at Screening and Eligibility.

10. Negative serum pregnancy test at Screening and Eligibility for females with reproductive potential, and agreement of all subjects to use a reliable form of contraception during the study and for 12 weeks after the last dose of study drug.

11. Able and willing to give adequate written informed consent, to communicate effectively with study personnel, and willing to be compliant with protocol requirements.

Exclusion Criteria

1. HIV-2 antibody positive at Screening Visit.

2. Positive hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody (if positive HCV antibody, HCV RNA must be negative).

3. Untreated syphilis infection (positive rapid plasma reagin [RPR]).

4. Changes in ART regimen due to virologic breakthrough.

5. History of lymph node irradiation or dissection.

6. Prior use of any HIV immunotherapy or vaccine within 9 months prior to Screening.

7. Prior participation in an AGS-004 clinical study.

8. Treatment interruption of ART for > 1 month since starting the ART from which the pre-ART plasma sample was drawn.

9. Any acute infection or medical illness within 14 days prior to Screening and throughout the pre-treatment evaluation phase (Step 1).

10. Initiation of ART during the acute HIV infection stage, if date of infection known (acute infection defined as < 6 months between date of HIV infection and ART start date).

11. Pregnancy or breast-feeding.

12. Receipt of any immune modulators or suppressors within 30 days prior to Screening and throughout the pre-treatment evaluation phase (Step 1).

13. Evidence of hepatic decompensation in cirrhotic subjects: history of ascites, hepatic encephalopathy, or bleeding esophageal varices, or screening laboratory results of any of the following:

• International Normalized Ratio (INR) of ≥ 1.5 X upper limit of normal (ULN);
• Serum albumin < 3.3 g/dL;
• Serum total bilirubin > 1.8 X ULN, unless history of Gilbert's disease or deemed related to treatment with atazanavir.

14. History or other clinical evidence of significant or unstable cardiac disease (e.g., angina, congestive heart failure, recent myocardial infarction, significant arrhythmia) or clinically significant electrocardiogram (ECG) abnormalities.

15. History of moderate or severe renal impairment (i.e., persistent history of creatinine clearance < 50 mL/min) or any other renal disorder deemed clinically significant by the investigator.

16. Prior history of an acquired immunodeficiency syndrome (AIDS) defining condition.

17. History or other evidence of severe illness, malignancy, immunodeficiency other than HIV, or any other condition that would make the subject unsuitable for the study in the opinion of the investigator.

18. Known allergy or sensitivity to the components of the investigational immunotherapy.

19. Active drug or alcohol use or dependence that would interfere with adherence to study requirements in the opinion of the investigator.

20. Use of systemic corticosteroids and use of topical steroids over a total area exceeding 15 cm² within 30 days prior to Screening.

21. Any investigational antiretroviral agents or use of a CCR5 inhibitor at Screening.

22. Active autoimmune disease or condition.

23. Participation in another investigational clinical study within the previous 30 days or use of investigational agents.

24. Body weight less than 30 kg.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Argos Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jeffery Jacobson, MD

Role: PRINCIPAL_INVESTIGATOR

Drexel University

Locations

UCDavis Research Office at CARES

Sacramento, California, United States

Jacobi & North Central Bronx Hospitals

The Bronx, New York, United States

AIDS Clinical Trials Unit

Chapel Hill, North Carolina, United States

Duke University Medical Center

Durham, North Carolina, United States

Division of Infectious Disease and HIV Medicine Partnership Comprehensive Care Practice

Philadelphia, Pennsylvania, United States

The Ottawa Hospital

Ottawa, Ontario, Canada

Clinique médicale l'Actuel

Montreal, Quebec, Canada

Clinique Médical du Quartier Latin

Montreal, Quebec, Canada

Montreal Chest Institute, Immunodeficiency Dept.

Montreal, Quebec, Canada

Countries

United States; Canada

Related Links

http://www.argostherapeutics.com/

Sponsor Website

Other Identifiers

HHSN266200600019C

Identifier Type: OTHER

Identifier Source: secondary_id

ES-11702

Identifier Type: OTHER

Identifier Source: secondary_id

AGS-004-003

Identifier Type: -

Identifier Source: org_study_id

NCT00595192

Identifier Type: -

Identifier Source: nct_alias